Which is better for depression: a pill or a therapy?

The best antidepressants have a high chance of being effective for depression, and they can also help people with other psychiatric disorders, according to research published Monday in the New England Journal of Medicine.

Researchers at Johns Hopkins University and Columbia University School of Medicine analyzed a clinical trial of the drug Zoloft, which was approved by the Food and Drug Administration in 2015 and is now being widely marketed.

The study was published in the journal Clinical Psychiatry.

Zolight is the most commonly prescribed antidepressant in the U.S. at more than 100 million pills sold per year.

It was one of the first antidepressants approved by President Trump and was the first to receive FDA approval in the United States.

In the study, the researchers analyzed data from more than 20,000 people, ages 18 to 74, who were randomly assigned to either take Zolofex or placebo for six weeks.

They also collected data on depression, anxiety and other symptoms.

Zoloft was also given to people with a family history of depression.

The trial found that the patients who received Zolfex had a significantly higher risk of a subsequent depression diagnosis, as well as a reduction in depression symptoms, compared with the people who received placebo.

The study also found that Zolfort was associated with a lower risk of dying from suicide, but it’s unclear whether this was because the drug was more effective at reducing depression symptoms or because it was effective at helping people with depression to live more independently.

The research is important because it shows that people can benefit from the medication, but also raises important questions about the drug’s long-term effectiveness and the potential for side effects.

The drugs have been prescribed for more than 30 years, and the drugs are highly addictive.

The FDA has said it is looking into whether they are safe and effective.

Zoë Quinn, a professor of psychiatry at Johns, said the study “clearly points to Zolos effectiveness in reducing depression and anxiety symptoms, but not at helping them to live independently, as the company claims.”

Zoloflex and Zoloff are sold by Johnson & Johnson and are approved for the treatment of severe depression and schizophrenia, according, to the company.

The drug is currently available only in Europe, and in the short term is more expensive than other antidepressants.

It’s not clear how many people in the study received Zolsoft, although the researchers noted that “we observed that the number of patients receiving the drug increased from a previous study of more than 25,000 to more than 65,000” in the first week of the study.

It’s possible that this was due to a more extensive follow-up study, which may have included additional patients.

Researchers also noted that patients on the drug had lower levels of depressive symptoms and less anxiety.

However, this is not known yet.

The results of the new study come as the FDA continues to work on a rule that will make it easier for patients to take Zolsofex.

This rule was proposed in June and is expected to be finalized in September.

It would allow people to take the drug for an average of six weeks, although some people have taken longer.

The rule is also expected to change the way the drugs work.

For the new trial, the Johns researchers looked at a more recent trial of Zolovax, a drug that was approved in 2016.

That study showed that patients with severe depression were more likely to be prescribed Zolovex than those who did not have severe depression.

In both trials, the participants received more than one pill a day, but the researchers did not measure the effects of the drugs on their mental health.

The researchers also said they were not sure whether Zoloprol and Zolsfex were effective at preventing the onset of depression and depression symptoms.

They noted that Zolsoex and Zolisfex appear to be effective, but they added that the longer-term outcomes in the current study are not clear.

The authors of the Johns study said they plan to follow up with more patients to see if the results of their study are the same.

The Johns study was funded by a National Institutes of Health grant, and it was supported by the Department of Veterans Affairs.

The Johns Hopkins team also reported receiving funding from the UAB Center for Neurosciences.